Drugs / NEXTGEN-TIL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05141474 | Oct 2021 → Jan 2027 expected | cancer, epithelial neoplasm | Vall d'Hebron Institute of Oncology | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEXTGEN-TIL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05141474 ↗ |
| Modality | Cell therapy | “NEXTGEN-TIL product is a cellular investigational product comprising a live cell suspension of autologous tumor-infiltrating lymphocytes derived from the patient's own tumor.” NCT05141474 ↗ |
| Route | Intravenous | “It will be administered IV on Day 0 (24h after the last dose of Fludarabine).” NCT05141474 ↗ |